Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Rhea-AI Summary

Hikma (HIK) welcomed a unanimous decision by the US Supreme Court that effectively ends Amarin’s patent infringement litigation over Hikma’s generic icosapent ethyl.

According to Hikma, the ruling confirms its ability to keep supplying its skinny‑label generic for severe hypertriglyceridemia to US patients.

Positive

• US Supreme Court unanimously ends Amarin patent case against Hikma
• Hikma can continue marketing its skinny-label generic icosapent ethyl in the US
• Litigation outcome supports US legal framework for skinny-label generic medicines
• Over 2,300 US Hikma employees’ work on generic portfolio can continue without this case overhang

Negative

• None.

News Market Reaction – HKMPY

-0.47%

-0.47% Session close to close

In the Jun 9 session, HKMPY declined 0.47%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on a unanimous Supreme Court decision in Hikma’s favor, effectively ending...

Analysis

This announcement centers on a unanimous Supreme Court decision in Hikma’s favor, effectively ending Amarin’s patent infringement case and affirming Hikma’s ability to market its generic icosapent ethyl for non‑patented uses. With shares trading below the 200-day MA at 45.42, investors may track how this legal clarity influences Hikma’s U.S. generic strategy. Past news, including a product launch that preceded a -2.29% move, shows that positive events do not always translate into immediate price gains.

Key Figures

US employees: 2,300 Generic launch year: 2020

2 metrics

US employees 2,300 Number of Hikma employees in the United States mentioned in the release

Generic launch year 2020 Year Hikma launched generic icosapent ethyl in the US

Historical Context

1 past event · Latest: Dec 08 (Positive)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 08	US product launch	Positive	-2.3%	Launch of FDA-approved TYZAVAN vancomycin premix product in US market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history shows at least one case where positive product news coincided with a negative price reaction.

Recent Company History

In the past six months, Hikma reported at least one notable U.S. product development. On Dec 8, 2025, it launched FDA-approved TYZAVAN™ (vancomycin injection, USP) in seven strengths with a 16‑month room-temperature shelf life. Despite the operationally positive nature of that update, the stock moved -2.29% over the following 24 hours, showing that upbeat product news has not always translated into immediate share gains.

Key Terms

icosapent ethyl, hypertriglyceridemia, fda approval, skinny label, +1 more

5 terms

icosapent ethyl medical

"The dispute between the companies involved Hikma's icosapent ethyl, a medicine made..."

Icosapent ethyl is a prescription medicine made from a purified omega‑3 oil that lowers high levels of blood fats called triglycerides and can lower the chance of certain heart problems in patients at risk. Think of it as a focused, doctor‑prescribed version of fish oil designed to treat a specific medical condition; for investors, its regulatory approvals, patent protection, clinical evidence and market uptake drive potential drug sales and influence a health‑care company’s revenue and valuation.

hypertriglyceridemia medical

"a medicine made from purified fish oil for people with severe hypertriglyceridemia."

An unusually high level of triglycerides — a type of fat carried in the bloodstream — that signals an increased risk of heart disease and related health problems. For investors, it matters because the size of the patient population, effectiveness of treatments, regulatory approvals, and insurance coverage can drive demand, clinical-trial outcomes, and revenue for drugmakers and medical-device companies; think of it like too much oil in an engine increasing the need for maintenance and repairs.

fda approval regulatory

"Hikma obtained FDA approval and in 2020 launched a generic version..."

FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.

skinny label regulatory

"This is known in the industry as a 'skinny label.'"

A skinny label is a regulatory approval for a medicine that allows it to be marketed only for some approved uses while deliberately excluding other uses that are still covered by another company's patent or exclusivity. Think of it like a cookbook that includes only a few allowed recipes so you don't copy a rival's secret dish; for investors this matters because it limits the drug’s addressable market, shapes pricing and revenue potential, and can reduce the risk of patent lawsuits or costly settlements.

patent infringement litigation regulatory

"ending Amarin's patent infringement litigation against the company."

A court dispute over whether one party copied or used another party’s patented invention without permission; think of it as a legal fight over who owns the recipe and who can sell products made from it. It matters to investors because outcomes can force a company to pay damages, share revenue, or stop selling a product, which can change future profits, cash needs and the value of the company’s stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United States effectively ending Amarin's patent infringement litigation against the company.

"Hikma has long fought for patients and their access to safe, high-quality, and affordable medicines," said Sam Park, General Counsel, Hikma. "We welcome the United States Supreme Court's decision, which allows us to continue providing millions of American patients with generic medicines that improve health and save lives."

"Our more than 2,300 US employees and their Hikma colleagues around the world remain hard at work developing, manufacturing and distributing essential generic medicines that have become a cornerstone of the US health care system and that serve the needs of hospitals, doctors, pharmacists and patients nationwide," said Mr. Park.

The dispute between the companies involved Hikma's icosapent ethyl, a medicine made from purified fish oil for people with severe hypertriglyceridemia. Hikma obtained FDA approval and in 2020 launched a generic version of Amarin's branded icosapent, Vascepa^® covering only the non-patented use of the medicine. This is known in the industry as a 'skinny label.' The law enabling skinny labelling is designed to bring cheaper medications to patients more quickly.

Amarin sued Hikma, wrongly alleging that Hikma was marketing the generic icosapent ethyl for both the patented and non-patented uses. A US district court dismissed Amarin's suit, but a federal appeals court overturned that ruling and allowed Amarin's case to proceed. Hikma then appealed to the Supreme Court.

"Hikma took this fight to the Supreme Court to ensure patients have ongoing access to generic medicines, especially those medicines that have appropriately carved out patented indications," continued Mr. Park. "Amarin's lawsuit sought to limit legitimate generic competition, despite long-established legal frameworks governing generic medicines in the US. We are very pleased the US Supreme Court has ended this litigation, which will have a beneficial impact on all Americans."

Hikma also thanks the many organizations and individuals who supported its position before the Court.

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal	+44 (0)20 7399 2760/ +44 7776 477050
EVP, Strategic Planning and Global Affairs
Steven Weiss	+1 732 788 8279
US Communications

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hikma-comments-on-supreme-court-of-the-united-states-unanimous-decision-in-favour-of-hikma-302792037.html

SOURCE Hikma Pharmaceuticals USA Inc.

FAQ

What did the US Supreme Court decide in the Hikma vs Amarin patent case (HIK)?

The US Supreme Court issued a unanimous decision effectively ending Amarin’s patent infringement litigation against Hikma. According to Hikma, this outcome confirms it may continue supplying its generic icosapent ethyl in the United States under its existing skinny-label approval.

How does the Supreme Court decision affect Hikma’s generic icosapent ethyl (HIK)?

The decision allows Hikma to keep marketing its FDA-approved skinny-label generic icosapent ethyl. According to Hikma, its product covers only non‑patented uses for severe hypertriglyceridemia, aligning with US laws designed to speed lower-cost generics to patients.

What is a skinny-label generic and how is Hikma using it for icosapent ethyl (HIK)?

A skinny-label generic is approved only for non‑patented uses of a medicine. According to Hikma, its icosapent ethyl was launched in 2020 as a skinny-label generic to Amarin’s Vascepa, focusing on the non‑patented indication for severe hypertriglyceridemia.

Why did Amarin sue Hikma over its generic icosapent ethyl product (HIK)?

Amarin sued alleging Hikma marketed its generic icosapent ethyl for patented and non‑patented uses. According to Hikma, Amarin’s lawsuit challenged legitimate generic competition despite established US legal frameworks that permit skinny-label approvals for non‑patented indications.

What does the Supreme Court ruling mean for US patients using Hikma’s generics (HIK)?

The ruling enables Hikma to continue offering its generic icosapent ethyl to US patients. According to Hikma, this supports ongoing access to affordable, high-quality medicines as part of its wider US generic portfolio serving hospitals, doctors, pharmacists and patients.

How many US employees does Hikma have supporting its generic medicines business (HIK)?

Hikma reports having more than 2,300 employees in the United States. According to Hikma, these employees develop, manufacture and distribute essential generic medicines that are described as a cornerstone of the US healthcare system and patient access to treatments.